Clinical trials
catalyst calendar across sponsors →Studies where UNH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 2 observational · 1 with posted results
Held by 30 tracked-famous managers (Dodge & Cox, EAGLE CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP, JANE STREET GROUP, LLC, +25 more) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · government filings 180d: 7 congress / 9 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-CareNCT04810026Change in mean glucose time in range from baseline at Week 6Randomized · Open-label · Treatment | Not applicable | Completed | Behavioral: Education, Meal delivery, Lifestyle coaching | PreDiabetes, Diabetes Mellitus, Type 2 | 41 | 2021-10-26actual | 2022-02-23 |
| A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for ResearchNCT04327804observationalDetection of SARS-CoV-2 virus | — | Completed | Diagnostic test: Odd/Even birth year intervention groups | SARS-CoV Infection | 139 | 2020-08-18actual | 2022-04-11 |
| PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With HydroxychloroquineNCT04353037results2021-10-19Substudy 1 - Number of COVID-19+ PCR Patients in Self-quarantine Who Are HospitalizedRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants. | Drug: Group 1 HCQ, Group 2 Placebo | Coronavirus, Corona Virus Infection | 39 | 2020-07-11actual | 2021-10-19 |
| Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic IndividualsNCT04321369observationalAccuracy of patient administered testsStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Diagnostic test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals | Infections, Respiratory, Fever, Cough | 530 | 2020-03-23actual | 2022-05-04 |
| Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in AdultsNCT01768546Change from Baseline Weight Measure at Week 16Randomized · Open-label · Prevention | Not applicable | Completed | Behavioral: Virtual Diabetes Prevention Program, Interactive tracking and problem solving web portal | Pre-diabetes | 306 | May 2013actual | 2014-12-19 |
| Evaluation of a Commercial Gaming Impact in a Childhood Obesity InterventionNCT01757925MVPARandomized · Open-label · Treatment | Phase 4 | Completed | Behavioral: weight managment program · Other: Active Gaming | Childhood Obesity | 77 | Sep 2012actual | 2012-12-31 |
| Community-based Program to Treat Childhood ObesityNCT01374646Change in weight and body mass index (BMI) in children and teens at 6 monthsNon-randomized · Open-label · Treatment | Not applicable | Completed | Behavioral: JOIN Intervention | Childhood Obesity | 155 | 2012-06-05actual | 2021-06-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19